Lrp5/6 co-receptor is known to play a role in bone formation and lipid metabolism. This gene encodes a member of the low-density lipoprotein (LDL) receptor gene family. This study tests the hypothesis that Lrp5/6 is necessary for the development of valve calcification in experimental hypercholesterolemia. Experimental hypercholesterolemia mouse models were tested: Lrp5 Synchrotron and positive gene expression for Lrp5/6 or Runx2. The double knockout ApoE À/À :Lrp5 À/À developed mild mineralization in the cholesterol treated valves with an increase in Lrp6 and Runx2 expression( P < 0.05). There was no mineralization in the right sided hearts valves. In conclusion Lrp5/6 is necessary for calcification in the aortic valve in the presence of experimental hypercholesterolemia. These data demonstrate the first mouse genetic evidence for the LDL-Density-Pressure theory in cardiac valves.
T he LDL-related receptor 5 and 6 (Lrp5 and Lrp6) genes were cloned in 1998 based on their homology with the low-density lipoprotein receptor (LDLR) Dong et al., 1998; Hey et al., 1998; Kim et al., 1998 ]. Mutations in either LRP5 or LRP6 proteins have caused a number of diseases processed in the field of bone [Gong et al., 2001; Little et al., 2002] , and have been associated with cardiovascular disease [Caira et al., 2006; Fujino et al., 2003; Kim et al., 1998; Rajamannan et al., 2005a] . The LDL-Density-Pressure theory [Rajamannan, 2011] combines the structure, function analysis of these co-receptors with the results from the genetic studies to provide a unique hypothesis for the role of these receptors in the heart. This study provides the genetic mouse evidence to demonstrate that in the presence of experimental hypercholesterolemia, Lrp5/6 receptors, Runx2 genes are upregulated to mediate calcification by MicroCT analysis.
heart, one leaflet from each aortic valve was fixed in 10% buffered formalin for 24 h and then embedded in paraffin. Valves were also snap frozen in liquid nitrogen and stored in À808 freezer for gene expression experiments and MicroCT Paraffin embedded sections (6mm) were cut and prepped for histopathology exam for Masson trichrome stain in the valves. Semi-quantitative PCR [Rajamannan et al., 2002 [Rajamannan et al., , 2005a and Realtime PCR [Hawse et al., 2008] were performed to measure Lrp5/6 and Runx2 in the cardiac valves. The ApoE À/À mice were not tested for the Lrp6 receptor as the study was completed prior to the data from the double knockout were available.
MICRO-CT
After fixing in formalin, the valves were examined using a Scanco MicroCT-40 system operated at 45 kV. Sampling was with $8 mm voxels (volume elements) and maximum sensitivity (1000 projections, 2048 samples, and 0.3 s/projection integration [Rajamannan et al., 2003] ) N ¼ 60 valves. Valve calcification was quantified using the Scanco MicroCT-40 system. MicroCT (micro Computed Tomography) is essentially a high-resolution version of clinical CT for smaller sample volumes. After recording a set of slices of the valve tissue, the total amount of mineralized tissue and the fraction of tissue mineralized in the sample will be determined using techniques employed in earlier valve studies [Caira et al., 2006; Rajamannan et al., 2005a] . One threshold will be used for the total tissue and a second for mineralized tissue, and the necessary computations will be performed using the Scanco system's software suite. The microstructure of mineralized valve tissue will also be characterized.
MICROCT SYNCHROTRON
MIcroComputed Tomography (MicroCT) was performed at station 2-BM of the Advanced Photon Source (APS, Argonne National Laboratory) for higher resolution when calcification was not detected by Scanco MicroCT 40 system. Each heart was removed from fluid and positioned securely within a sealed plastic tube. Data were collected using the following parameters: 15 keV photons and rotation over 1808 in 0.128 increments. The sample-detector separation was $50 mm (in order to produce sufficient X-ray phase contrast to differentiate different soft tissue types), and reconstruction was on a (2K) 2 grid with $2.8 mm isotropic volume elements (voxels). 
RESULTS

To understand if Lrp5
DISCUSSION
The LDL co-receptor Lrp5/6 is a member of the family of structurally closely related cell surface LDL receptors that have diverse biological functions in different organs, tissues, and cell types which are important in development and disease mechanisms. The most prominent role in this evolutionary ancient family is cholesterol homeostasis. The LRP5 pathway regulates bone formation in different diseases of bone [Gong et al., 2001; Boyden et al., 2002] . The discovery of the LRP5 receptor in the gain of function [Boyden et al., 2002] and loss of function [Gong et al., 2001 ] mutations in the development of bone diseases, resulted in a number of studies which have shown that activation of the canonical Wnt pathway is important in osteoblastogenesis [Babij et al., 2003; Fujino et al., 2003; Holmen et al., 2004; Westendorf et al., 2004] . Three studies to date have confirmed the regulation of the LRP5/Wnt pathway for cardiovascular calcification in vivo and ex vivo [Rajamannan et al., 2005a; Caira et al., 2006; Shao et al., 2005] . Lrp5 has been shown to have an effect on bone mass via the mechanostat effect on regulating bone formation. The findings in the human of the high bone mass gain of function mutation [Little et al., 2002] , led to a series of discoveries that Lrp5 regulates bone mass via the mechanical force effect on the receptor [Akhter et al., 2004; Johnson et al., 2004; Johnson and Summerfield, 2005] . Lrp6 also regulates bone but has been found to have a low bone mass effect in patients in which a putative partial loss-of-function mutation in LRP6 was identified to early cardiovascular-related death associated with increased plasma LDL, triglycerides, hypertension, diabetes, and osteoporosis [Mani et al., 2007] The right-sided valves in all of the specific mice did not develop any calcification, which further demonstrates the role of the higher pressures in the left side of the heart to activate the Lrp5/6 receptor in the valve. LRP5 binds apoE-containing in vitro and is widely expressed in many tissues including hepatocytes, adrenal gland and pancreas [Kim et al., 1998 ]. The production of mice lacking LRP5 revealed that LRP5 deficiency led to increased plasma cholesterol levels in mice fed a high-fat diet, secondary to decreased hepatic clearance of chylomicron remnants and also marked impaired glucose tolerance [Fujino et al., 2003 ]. In the LRP5 mice that were not fed the high cholesterol diet, the mice did not develop high cholesterol levels [Magoori et al., 2003] . The investigators went on to define the role of LRP5 in the lipoprotein metabolism by developing a double knockout mouse for ApoE:LRP5. They found that the double KO mouse had approximately 60% higher cholesterol levels compared with the age matched apoE knockout mice. High performance liquid chromatography analysis of plasma lipoproteins revealed that no difference in the apoproteins but the cholesterol levels in the very low density and LDL fractions were markedly increased in the apoE:Lrp5 double KO mice. There was 3-fold increase in the atherosclerosis indicating that the Lrp5 mediates both apoE-dependent and apoE-independent catabolism of lipoproteins. In this current study performed the serum cholesterol levels demonstrated marked increase in the cholesterol in both of the ApoE À/À and the ApoE:Lrp5 double KO mice further confirming the association of elevated cholesterol and the mineralization process.
In 1994, studies demonstrated that the plasma cholesterol levels in the double KO mice lacking both ApoE and LDLR were not significantly different from the levels in the ApoE knockout mice [Ishibashi et al., 1994] . In summary, we have previously shown that that osteoblastogenesis and chondrogenesis are critical in calcific aortic valve disease(CAVD). The osteoblast phenotype in CAVD is secondary to the activation of mesenchymal osteogenic gene [Rajamannan, 2011] to indicate a biologic-hemodynamic foundation for the mechanism of Lrp5/6 activation in the heart.
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